Indiana University School of Medicine researchers at the school's South Bend regional campus, in collaboration with colleagues at the University of Notre Dame, have identified a new therapeutic target ...
Referral to a PH expert centre, including for right heart catheterisation, confirms the diagnosis. Supportive measures include diuretic therapy for symptoms of right heart failure and fluid retention, ...
WILMINGTON, N.C. (WECT) - Most people are familiar with doctors using a cuff around the wrist to check blood pressure, a practice that can detect systemic hypertension. Dr. Lisa Rose-Jones, with ...
Interstitial lung disease (ILD) refers to a group of conditions that cause damage and stiffness in the lung tissue. Over time, this damage can make it harder for oxygen to move into the bloodstream.
Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within ...
Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...
Adults with pulmonary arterial hypertension (PAH) have a new treatment available with the FDA approval of sotatercept (Winrevair; Merck), an activin signaling inhibitor biologic. PAH is a ...
Researchers estimate that about 1% of the global population has pulmonary hypertension — a disease caused by high blood pressure in the blood vessels that deliver oxygen to the lungs. Past studies ...
Liquidia Corporation has announced that its inhalation powder YUTREPIA™ (treprostinil) is now available for prescription at specialty pharmacies, following FDA approval on May 23, 2025, for treating ...
The FDA has approved YUTREPIA™ (treprostinil) inhalation powder, developed by Liquidia Corporation, as a treatment option for adults with pulmonary arterial hypertension (PAH) and pulmonary ...
Mere weeks after earning the FDA’s signoff on new drug Winrevair to treat pulmonary arterial hypertension (PAH), Merck has kicked off an educational campaign around the rare disease. The “Outnumber ...
Lindsay talks about the difficult road of managing a pulmonary arterial hypertension diagnosis, and how a newly discovered medication helped secure her future.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results